Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
InMed Pharmaceuticals ( (INM) ) has issued an update.
InMed Pharmaceuticals has published a study revealing the potential of cannabinol (CBN) as an anti-inflammatory agent for skin diseases. The research highlights how CBN modulates the endocannabinoid system, showing promise for treating conditions like psoriasis and atopic dermatitis. This development could pave the way for therapeutic and cosmetic applications, underscoring CBN’s role in regulating skin inflammation and offering protective benefits.
Learn more about INM stock on TipRanks’ Stock Analysis page.